[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][N][C@H1][C][C@@H1][Branch2][Ring1][O][S][=Branch1][C][=O][=Branch1][C][=O][C][=C][Ring1][Branch2][C][=C][Branch1][Ring2][S][Ring1][Branch1][S][=Branch1][C][=O][=Branch1][C][=O][N][C]"}, {"from": "gpt", "value": "The molecule is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects. First marketed in 1995, dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt or in combination with [timolol] as Cosopt PF."}]